Rasagiline Tablets

SOL #: SPE2D2-26-D-0011Award Notice

Overview

Buyer

DEPT OF DEFENSE
Defense Logistics Agency
DLA TROOP SUPPORT
PHILADELPHIA, PA, 19111, United States

Place of Performance

Delran, NJ

NAICS

Pharmaceutical Preparation Manufacturing (325412)

PSC

Drugs And Biologicals (6505)

Set Aside

No set aside specified

Timeline

1
Posted
Apr 2, 2026

Qualification Details

Fit reasons
  • NAICS alignment with historical contract wins in similar service areas.
  • Scope strongly matches core technical capabilities and delivery model.
Risks
  • Past performance thresholds may require one additional teaming partner.
  • Potential clarification needed on staffing minimums before bid/no-bid.
Next steps

Validate eligibility requirements, assign capture owner, and schedule partner outreach to confirm teaming strategy before submission planning.

Quick Summary

The Defense Logistics Agency (DLA) Troop Support has awarded contract SPE2D2-26-D-0011 for Rasagiline Tablets to Golden State Medical Supply, Inc., with a total value of $6,637,357.21. This award is for pharmaceutical prime vendor services, specifically for Rasagiline 0.5 MG and 1 MG tablets, and is based on Solicitation SPE2D2-25-R-0020.

Scope of Work

This contract covers the procurement of:

  • Rasagiline 0.5 MG Tablets (30 count bottle)
  • Rasagiline 1 MG Tablets (30 count bottle)

Quantities specified in the schedule are estimates only, indicating a requirements-type contract.

Contract & Timeline

  • Contract Type: Requirements-type contract (based on estimated quantities)
  • Period of Performance: Estimated 5 years
  • Total Award Amount: $6,637,357.21
  • Award Date: April 2, 2026
  • Set-Aside: UNRESTRICTED (not set aside for small businesses)
  • Place of Performance: Delran, NJ

Award Details

The award was made to Golden State Medical Supply, Inc. (Distributor/Packer), with Carnegie Pharmaceuticals, LLC identified as the manufacturer. The selection was based on Golden State Medical Supply, Inc.'s final proposal revision dated February 18, 2026.

Additional Notes

The contract incorporates by reference FAR 52.212-1, 52.212-4, and 52.212-5. A comprehensive list of applicable FAR and DFARS clauses is included, detailing various requirements and restrictions. Appendix A of the award document lists current Pharmaceutical Prime Vendors.

Contact Information

People

Points of Contact

Kyle LewickiPRIMARY
Jason WraySECONDARY

Files

Files

Download

Versions

Version 1Viewing
Award Notice
Posted: Apr 2, 2026
Rasagiline Tablets | GovScope